Catégorie : Biotech

FABENTECH

by jbertholdin Biotech, Pharma

FABENTECH

About the company

Headquartered in Lyon, France, Fabentech, established in 2009, is a leading biopharmaceutical company specializing in the development and production of emergency treatments to combat the most critical biological threats to public health. Their innovative Fabshield® platform is a safe and fully validated polyclonal antibody technology aiming to produce highly purified polyclonal antibodies capable of neutralizing viruses, toxins, and their potential variants, thereby halting disease progression.

Fabentech’s mission is to collaborate closely with governments and healthcare organizations, delivering timely and effective medical countermeasures to address bioterrorism agents and emerging infectious diseases during emergency situations. Their integrated R&D capabilities and proprietary manufacturing site enable them to rapidly deploy biodefense and pandemic preparedness solutions against diverse targets, ensuring reliable protection and treatment options in the face of escalating risks.

About the solution

Fabentech’s produces broad-spectrum polyclonal antibodies that have proven to be effective against rapidly mutating pathogens or toxins with multiple variants.

FABENTECH has the largest pipeline of medical countermeasures in Europe for:
– Biodefense
– FBT-002, antitoxin program funded by the French Army against a plant-based toxin. Late-stage clinical phase with MA planned in 2025
– FBT-003, antitoxin program funded by the European Defense Fund. Status: PoC
– FBT-004, undisclosed antitoxin program.
– Antivirals
– Nipah virus infections, status: PoC
– Pan-sarbevovirus infections, status: discovery
– FabenFlu® a fully developed treatment against H5N1 avian flu with ODD status in Europe

Website
Key information

–  Therapeutic areas: Infectious Diseases, Intoxications, Biodefense

–  Based in: Lyon (FRANCE)

–  Employees: 11 -50

–  Created in: 2009

CHELATEC

by jbertholdin Biotech, Pharma

CHELATEC

About the company

With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities.

About the solution

Their services cover/include:
– Bioconjugation
– Radioactive labeling
– Analytical controls (HPLC, iTLC/TLC, SDS-PAGE…)
– Stability studies (storage stability, plasma stability)
– In vitro assays (Binding affinity, IRF, internalization, cytotoxicity, autoradiography on tissue sections)
– In vivo investigations (Pharmacokinetics, biodistribution, efficacy, dosimetry)

Website
Key information

–  Therapeutic areas: Oncology, Targeted therapy

–  Based in: Saint-Herblain (FRANCE)

–  Employees: 11 -50

–  Created in: 2000

THERANEXUS

by jbertholdin Biotech, Pharma

THERANEXUS

About the company

Theranexus is a French biopharmaceutical company discovering and developing treatments to meet the needs of patients with rare neurological disorders.

About the solution

Their lead asset is an exclusive first liquid formulation of miglustat developed in Niemann Pick C and Batten diseases

Website
Key information

–  Therapeutic areas: Central nervous system (CNS)

–  Based in: Lyon (FRANCE)

–  Employees: 11 -50

– Created in: 2013

CYNBIOSE

by jbertholdin Biotech, CRO/CDMO, Pharma

CYNBIOSE

About the company

Cynbiose is a preclinical CRO specialized in non-human primate (NHP) translational models for biomedical research since 2008. They maintain a France-based AAALAC-accredited animal facility for toxicological studies. Their brand new state-of-the-art facility can also accommodate studies requiring biosafety environments from ABSL-1 to 3, as well as GMOs such as viral vector-based gene therapies.

About the solution

The NHP model is well suited to predict pharmacokinetic and pharmacodynamic parameters, guide the selection of a safe starting dose for FIH trials, and provide valuable data on the potential toxicity of the candidate.

Their non-GLP preclinical services include:

– Pharmacokinetics (PK, central pharmacokinetics) and pharmacodynamics (PD) profiles

– In vivo biodistribution studies: biodistribution pattern (tissues, fluids such as CSF), Kpuu determination, and non-invasive imaging technologies

– Preclinical safety assessment, DRF, MTD, immunotoxicity, immunogenicity studies

– Immunopharmacology models

– Dedicated solutions: Nose-to-brain delivery strategies, Inhaled products, Gene therapies

Their state-of-the-art France-based animal facility has been AAALAC accredited since 2015. Their proven platform can operate studies in biosafety levels up to level 3, as well as GMOs C1-2, in a GLP-like environment.

Cynbiose combines ten years of preclinical experience and a wide range of cutting-edge capabilities to serve biopharmaceutical companies. Driven by passion and curiosity for science, their sponsors value them as trusted, reliable, flexible, and innovative partners.

Website
Key information

–  Therapeutic areas: Central nervous system (CNS), Oncology, Infectious diseases, Respiratory diseases, Immune disorders & inflammation

–  Based in: Marcy l’Etoile (FRANCE)

–  Employees: 11 -50

– Created in: 2008

THERAVIA (ADDMEDICA)

by jbertholdin Biotech, Pharma

THERAVIA (ADDMEDICA)

About the company


THERAVIA is a European-based company dedicated to the development, marketing, and distribution of innovative and original products dedicated to serious conditions, rare diseases, and unmet medical needs. Formed in 2023 through the merger of two French companies (ADDMEDICA and CTRS), they benefit from their track records in drug development, registration, and commercialization, as well as from a strong hospital presence and a solid KOL network, especially for rare disorders. They also benefit from a robust commercial network in all countries of Western Europe.

They are supported by MERIEUX EQUITY PARTNERS as a reference shareholder to accelerate their growth in France and internationally. To expand their portfolio, they are now looking for new products with the following features:

– Designed to treat a limited number of patients

– And/or highly innovative products

– And/or addressing emerging markets with few competitors and requiring specialized sales & distribution processes

About the solution

Theravia is a leader in some rare diseases’ treatment, having, for example, marketed a safe and easy-to-dose form of hydroxyurea called « Siklos » in Europe, the US (https://siklosusa.com/), and other territories to treat sickle cell disease. They invest in large clinical trials to advance the knowledge of the disease and its treatment. For instance, they are conducting ESCORT-HU, a Phase IV observational cohort study that includes more than 2,000 patients.

Website
Key information

–  Therapeutic areas: Rare diseases, Neglected disorders, Paediatric diseases

–  Based in: Ile de France (FRANCE)

–  Employees: 11 -50

– Created in: 2005

HTL BIOTECHNOLOGY

by jbertholdin Biotech, Pharma

HTL BIOTECHNOLOGY

About the company

HTL Biotechnology is a French biotech company and world leader in the development and responsible bioproduction of pharmaceutical-grade biopolymers. These biopolymers are used by healthcare companies for the development of treatments in a wide range of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics, and rheumatology.

For over 30 years, HTL Biotechnology has been a driving force for innovation in the sector, collaborating with research entities and biotech companies to address tomorrow’s medical needs (regenerative medicine, drug delivery, etc.). HTL Biotechnology is a fast-growing international company, exporting nearly 80% of its production to over 30 countries. To meet these growing global needs for biopolymers, HTL Biotechnology has also established subsidiaries in Singapore and the United States, including the construction of a production unit for a neuromodulator. Historically based in Javené (Brittany), the company consolidates production, innovation, research and development, and quality activities on-site. HTL Biotechnology employs nearly 300 collaborators worldwide.

About the solution

Biopolymers are at the heart of today’s and tomorrow’s therapeutic innovations, HTL Biotechnology offers:

Today’s portfolio: pharmaceutical-grade hyaluronic acid, PN & PDRN, cosmetic-grade sodium DNA

Quality is essential, and HTL guarantees that all its products comply with the highest quality standards and good manufacturing practices (GMP-compliant). Our commitment to safety and excellence is proven: no batch recalls in three decades, auditing and certification by regulatory bodies such as the FDA (USA). – Innovation portfolio: heparosan, oligo-HA – Biopolymer platform service: HTL offers expert advice and support to companies wishing to embark on the industrial production of a modified hyaluronic acid compound.

Website
Key information

–  Therapeutic areas: Ophthalmology, Dermatology, Medical Aesthetics, Rheumatology

–  Based in: Javené (FRANCE) Subsidiary : HTL BMI based in Massachusetts (US)

–  Employees: 201 – 500

– Created in: 1992

CROSSJECT

by jbertholdin Biotech, Pharma

CROSSJECT

About the company

Crossject SA is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing.
The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.

About the solution

ZENEO is a pre-set in factory needle free device, it enables the easy and safe injection of a drug in only two steps, press and push into the injection site, even through clothing if necessary.

ZENEO has demonstrated through several Human Factors studies that it can be used easily and quickly even by naïve users even during an emergency situation.

There is no needle, which is a real advantage in terms of risk of laceration during injection and/or potential cross-contamination for the rescuer, or further down the disposal chain.

Website
Key information

–  Therapeutic areas: Epilepsy, Allergy, Endocrinology, Asthma

–  Based in: Dijon (FRANCE) Affiliate in Boston (USA)

–  Employees: 51 – 200

– Created in: 2001

ALTEVAX BIOTECH

by jbertholdin Biotech, Pharma

ALTEVAX BIOTECH

About the company

ALTEVAX was founded in 2016 by Professor Antoine Carpentier, neuro-oncologist and Head of the Neurology Department at Saint-Louis Hospital in Paris (AP-HP). His research on biological nanoparticles and melanin’s potential as adjuvant for vaccines resulted in a patented antigen-melanin platform technology.

Since 2016, the research team at ALTEVAX has demonstrated melanin’s ability to shield antigens from degradation and transport them to the lymph nodes, where they induce a robust and specific immune response involving CD4 and CD8. ALTEVAX technology is protected by two families of general patents and can be used in a wide range of new vaccines depending on the antigens selected.

ALTEVAX lead product, a therapeutic vaccine against Glioblastoma, based on the tumor-associated antigen TERT (from the telomerase complex), has completed the final stage of preclinical development, and will enter a Phase 1/2a clinical trial in newly diagnosed glioblastoma in Q3 2024.

About the solution

ALTEVAX technology, peptide-based vaccines using melanin as adjuvant triggers a specific immune response, involving CD4+ and CD8+ lymphocytes, against self-antigens that is more effective and faster than current vaccine technology using emulsions, RNA (primarily producing antibodies and few CD8+), or DNA as messenger vectors. Laboratory experiments confirmed its superior efficacy.

Melanin induces an immune reaction similar to the reaction by the human body when defending against pathogenic aggressions. It is a natural, non-toxic product and offers an excellent benefit-to-risk ratio.

ALTEVAX mastered the production process for synthetic melanin and its combination with peptides. Its vaccines will be administered subcutaneously, simplifying administration, and reducing costs.

Website
Key information

–  Therapeutic areas: Oncology, Therapeutic Vaccine, Immuno-Oncology, Immunotherapy, Adjuvant Platform, Glioblastoma

–  Based in: Paris (FRANCE)

–  Employees: 1 – 10

– Created in: 2016

NETRIS PHARMA

by jbertholdin Biotech, Pharma

NETRIS PHARMA

About the company

Netris Pharma is a clinical-stage company developing innovative therapeutics to improve treatment outcome for cancer patients, targeting resistance to both chemotherapy and immunotherapy.

About the solution

Their lead asset, NP137, is a first-in-class anti-Netrin1 monoclonal antibody currently investigated in a randomized phase II in Endometrial and Cervical cancers as well as in 5 exploratory trials.

Website
Key information

–  Therapeutic areas: Oncology and Women Health

–  Based in: Lyon (FRANCE)

–  Employees: 11 – 50

– Created in: 2008

ALZPROTECT

by jbertholdin Biotech, Pharma

ALZPROTECT

About the company

Alzprotect, established in 2007 in Lille, France, focuses on creating therapies to slow or halt neurodegenerative diseases and rejuvenate brain function. Alzprotect is dedicated to innovating in the neurodegenerative field. The company holds 4 international patent families for its developed drugs and their global indications.

About the solution

Alzprotect is making strides with AZP2006 (EZEPROGIND), a novel oral synthetic molecule aimed at enhancing lysosome homeostasis by regulating Progranulin and its chaperone protein, Prosaposin. Unlike traditional treatments that target symptoms like amyloid peptides or Tau protein, AZP2006 focuses on the root processes of neurodegeneration. It has shown promising results in reducing amyloid peptide secretion, lowering hyperphosphorylated Tau protein levels, and decreasing neuroinflammation, thus offering a comprehensive treatment approach. Granted « orphan drug » status in Europe and the US for Progressive Supranuclear Palsy (PSP), its safety and efficacy have been proven in human trials, paving the way for Phase 2B/3 trials for PSP and future applications in Parkinson’s disease, Alzheimer’s disease, and amyotrophic lateral sclerosis.

Website
Key information

–  Therapeutic areas: Neurodegenerative diseases, Alzheimer’s disease, Progressive Nuclear Palsy, Parkinson’s disease

–  Based in: Loos (FRANCE), Boston (US)

–  Employees: 1 – 10

– Created in: 2007